The vitamin D receptor (VDR), initially identified as a nuclear receptor for 1α,25-dihydroxyvitamin D3 [1α,25(OH) 2D3], regulates calcium metabolism, cellular proliferation and differentiation, immune responses, and other physiological processes. Recently, secondary bile acids such as lithocholic acid (LCA) were identified as endogenous VDR agonists. To identify structural determinants required for VDR activation by 1α,25(OH)2D3 and LCA, we generated VDR mutants predicted to modulate ligand response based on sequence homology to pregnane X receptor, another bile acid-responsive nuclear receptor. In both vitamin D response element activation and mammalian two-hybrid assays, we found that VDR-S278V is activated by 1α,25(OH) 2D3 but not by LCA, whereas VDR-S237M can respond to LCA but not to 1α,25(OH)2D3. Competitive ligand binding analysis reveals that LCA, but not 1α,25(OH)2D3, effectively binds to VDR-S237M and both 1α,25(OH)2D 3 and LCA bind to VDR-S278V. We propose a docking model for LCA binding to VDR that is supported by mutagenesis data. Comparative analysis of the VDR-LCA and VDR-1α,25(OH)2D3 structure-activity relationships should be useful in the development of bile acid-derived synthetic VDR ligands that selectively target VDR function in cancer and immune disorders without inducing adverse hypercalcemic effects.
ASJC Scopus subject areas
- Molecular Biology
- Endocrinology, Diabetes and Metabolism